Abstract
Approximately 70% of all patients with myelodysplastic syndrome (MDS) present with lower-risk disease. Some of these patients will initially respond to treatment with growth factors to improve anemia but will eventually cease to respond, while others will be resistant to growth factor therapy. Eventually, all lower-risk MDS patients require multiple transfusions and long-term therapy. While some patients may respond briefly to hypomethylating agents or lenalidomide, the majority will not, and new therapeutic options are needed for these lower-risk patients. Our previous clinical trials with ezatiostat (ezatiostat hydrochloride, Telentra®, TLK199), a glutathione S-transferase P1-1 inhibitor in clinical development for the treatment of low- to intermediate-risk MDS, have shown significant clinical activity, including multilineage responses as well as durable red-blood-cell transfusion independence. It would be of significant clinical benefit to be able to identify patients most likely to respond to ezatiostat before therapy is initiated. We have previously shown that by using gene expression profiling and grouping by response, it is possible to construct a predictive score that indicates the likelihood that patients without delet...Continue Reading
References
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Feb 12, 2005·Blood·Wei TongHarvey F Lodish
Jun 29, 2005·British Journal of Haematology·Murat O Arcasoy, Xiaohong Jiang
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Oct 6, 2005·Blood·Kathryn E BoydArchibald S Perkins
Mar 15, 2006·Cancer·Hagop KantarjianHussain Saba
Mar 25, 2006·Nature Reviews. Cancer·Aurora Esquela-Kerscher, Frank J Slack
Apr 13, 2006·Blood·Bruce D ChesonHagop Kantarjian
May 2, 2006·The Journal of Biological Chemistry·Alix GazelMiroslav Blumenberg
Oct 6, 2006·The New England Journal of Medicine·Alan ListUNKNOWN Myelodysplastic Syndrome-003 Study Investigators
May 8, 2007·Cancer Research·Matilde Y FolloAlberto M Martelli
Sep 26, 2007·Blood·Azra RazaAlan F List
Feb 15, 2008·PLoS Medicine·Benjamin L EbertAzra Raza
Feb 27, 2008·The Journal of Experimental Medicine·Ryan M O'ConnellDavid Baltimore
Jan 17, 2009·Cancer Research·Christopher D ScharerCarlos S Moreno
Oct 23, 2009·Nature·David A BarbieWilliam C Hahn
Nov 6, 2009·Cancer Research·Yi-Wen HuangTim H-M Huang
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Anita WolferSridhar Ramaswamy
Apr 21, 2010·Cell Cycle·Junjie WuJining Lü
Nov 16, 2010·Nature Medicine·Zainab JaganiMarion Dorsch
Nov 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yoon-Jae ChoScott L Pomeroy
Jan 19, 2011·Cell·Noa NovershternBenjamin L Ebert
Feb 8, 2011·Blood·Karin VargovaTomas Stopka
Mar 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pablo TamayoJill P Mesirov
Jul 15, 2011·Blood·Pierre FenauxUNKNOWN MDS-004 Lenalidomide del5q Study Group
Sep 3, 2011·Cancer·Azra RazaMikkael Sekeres
Citations
Jul 12, 2013·Journal of Hematology & Oncology·Lohith BachegowdaAmit Verma
Mar 1, 2015·Expert Opinion on Investigational Drugs·Daruka Mahadevan, Gregory Ryan Sutton
Oct 20, 2012·Seminars in Hematology·Austin G Kulasekararaj, Ghulam J Mufti
Dec 3, 2014·Biochimica Et Biophysica Acta·Zhi-Wei YeKenneth D Tew
Dec 11, 2013·Biochimica Et Biophysica Acta·Dan ChenLan Luo
Sep 14, 2018·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Carmen Mariana Aanei, Lydia Campos Catafal
May 24, 2018·Cardiovascular & Hematological Disorders Drug Targets·Ota Fuchs
Nov 24, 2012·Nature Reviews. Cancer·Azra Raza, Naomi Galili
Jul 5, 2017·Expert Opinion on Pharmacotherapy·Natalie UyThomas Prebet